Atopic dermatitis (AD), the most common chronic inflammatory skin disease, is driven by
both terminal keratinocyte differentiation defects and strong type 2 immune responses. In …

Introduction: Atopic dermatitis (AD) is the most common inflammatory skin disease. It has a
complex pathophysiology, with a combination of immune dysregulation and intrinsic barrier …

Background Dupilumab is an IL-4 receptor α mAb inhibiting signaling of IL-4 and IL-13, key
drivers of type 2–driven inflammation, as demonstrated by its efficacy in patients with …

Background Atopic eczema is a common and debilitating condition associated with
depression and anxiety, but the nature of this association remains unclear. Objective To …

Atopic dermatitis (AD) is a common chronic inflammatory skin disease that predominantly
affects children. However, it can persist in adulthood and/or start at older ages. Due to its …

Background Moderate-to-severe atopic dermatitis (AD) has been associated with significant
disease burden and systemic abnormalities and often requires systemic treatments …

Atopic dermatitis (AD) is a type 2 chronic skin disorder associated with systemic and
psychosocial comorbidities decreasing the quality of life for many patients. Dupilumab, a …

Chronic hand eczema (CHE) is a common and burdensome inflammatory skin condition
seen in up to 10% of the population, more often in high-risk occupational workers. Topical …

Background: Atopic dermatitis is a chronic, relapsing and remitting disease that can be
difficult to treat despite a recently approved biologic therapy targeting IL-4/IL-13 receptor …

Dupilumab attenuates itch and skin inflammation in patients with atopic dermatitis (AD).
However, itch-related events that are improved by dupilumab remain unclear. Therefore, the …